Orion Oyj (LON:0M2N)

Market Cap	9.65B +17.4%
Revenue (ttm)	1.77B +22.7%
Net Income	505.54M +55.3%
EPS	3.59 +55.1%
Shares Out	n/a
PE Ratio	19.10
Forward PE	18.21
Dividend	1.57 (2.30%)
Ex-Dividend Date	Oct 19, 2026

Volume	103
Open	80.80
Previous Close	79.90
Day's Range	79.60 - 80.80
52-Week Range	56.50 - 82.20
Beta	0.30
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 28, 2026

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. It offers pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Quetiapine products for antipsychoti...

• Industry: Pharmaceutical Preparations
• Founded: 1917
• Employees: 4,000
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0M2N

Financial Performance

In 2025, Orion Oyj's revenue was 1.89 billion, an increase of 22.50% compared to the previous year's 1.54 billion. Earnings were 500.30 million, an increase of 51.65%.

Financial numbers in EUR

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 6, 2026

Data Sources Report a data error